Neuberger Berman Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Neuberger Berman Group’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-684,321	Closed	-$14.7M	–	2168
2025 Q4	$14.7M	Sell	684,321 -4,667	-0.7%	-$90.6K	0.01%	714
2025 Q3	$10.5M	Buy	688,988 +10,872	+2%	+$141K	0.01%	787
2025 Q2	$6M	Buy	678,116 +1,484	+0.2%	+$13K	﹤0.01%	914
2025 Q1	$5.3M	Buy	676,632 +192,487	+40%	+$1.61M	﹤0.01%	922
2024 Q4	$5.09M	Buy	+484,145	New	+$5.88M	﹤0.01%	960
2014 Q4	–	Sell	-63,300	Closed	-$905K	–	1641
2014 Q3	$905K	Sell	63,300 -16,600	-21%	-$239K	﹤0.01%	1269
2014 Q2	$1.2M	Buy	79,900 +2,900	+4%	+$35K	﹤0.01%	1221
2014 Q1	$1.03M	Buy	+77,000	New	+$825K	﹤0.01%	1211

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Neuberger Berman Group's AVDL Position: Q1 2026 in Review

Neuberger Berman Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 684,321 shares — an estimated $14.7M sold.

Neuberger Berman Group first reported a position in AVDL in Q1 2014 and held it in 8 quarters. The position peaked at $14.7M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Neuberger Berman Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Neuberger Berman Group sold 684,321 Avadel Pharmaceuticals shares in Q1 2026, an estimated $14.7M.
Neuberger Berman Group first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Neuberger Berman Group's Avadel Pharmaceuticals position peaked at $14.7M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.